Insider · CIK 0001951238

Chakma Justin

Reports to the SEC for 1 company · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001951238

Forms 4 and 5

Insider transactions

42 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-01-02	SPRYARS Pharmaceuticals, Inc. · Stock option (right to buy)A Award	Chief Business Officer	AAward	+240K sh	—	—	240,000
2025-11-12	SPRYARS Pharmaceuticals, Inc.S Sale	Chief Business Officer	SSale	−136K sh	$8.86	−$1.21M	0
2025-11-12	SPRYARS Pharmaceuticals, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+30K sh	$0.84	+$25.2K	166,380
2025-11-12	SPRYARS Pharmaceuticals, Inc.S Sale	Chief Business Officer	SSale	−30K sh	$8.91	−$267K	136,380
2025-11-12	SPRYARS Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−30K sh	—	—	89,047
2025-01-02	SPRYARS Pharmaceuticals, Inc. · Stock option (right to buy)A Award	Chief Business Officer	AAward	+274K sh	—	—	274,100
2024-12-13	SPRYARS Pharmaceuticals, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+27.3K sh	$1.44	+$39.3K	163,652
2024-12-13	SPRYARS Pharmaceuticals, Inc.S Sale	Chief Business Officer	SSale	−27.3K sh	$12.06	−$329K	136,380
2024-12-13	SPRYARS Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−27.3K sh	—	—	55,461
2024-12-12	SPRYARS Pharmaceuticals, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+117K sh	$0.84	+$98.6K	253,713
2024-12-12	SPRYARS Pharmaceuticals, Inc.S Sale	Chief Business Officer	SSale	−117K sh	$12.27	−$1.44M	136,380
2024-12-12	SPRYARS Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−117K sh	—	—	119,047
2024-12-10	SPRYARS Pharmaceuticals, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+50K sh	$0.84	+$42K	186,380
2024-12-10	SPRYARS Pharmaceuticals, Inc.S Sale	Chief Business Officer	SSale	−50K sh	$13.15	−$658K	136,380
2024-12-10	SPRYARS Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−50K sh	—	—	0
2024-12-06	SPRYARS Pharmaceuticals, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+50K sh	$0.84	+$42K	186,380
2024-12-06	SPRYARS Pharmaceuticals, Inc.S Sale	Chief Business Officer	SSale	−50K sh	$14.23	−$712K	136,380
2024-12-06	SPRYARS Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−50K sh	—	—	50,000
2024-12-05	SPRYARS Pharmaceuticals, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+49.6K sh	$0.84	+$41.7K	186,020
2024-12-05	SPRYARS Pharmaceuticals, Inc.S Sale	Chief Business Officer	SSale	−49.6K sh	$14.13	−$702K	136,380
2024-12-05	SPRYARS Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−49.6K sh	—	—	100,000
2024-12-04	SPRYARS Pharmaceuticals, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+45K sh	$0.84	+$37.8K	181,380
2024-12-04	SPRYARS Pharmaceuticals, Inc.S Sale	Chief Business Officer	SSale	−45K sh	$13.95	−$628K	136,380
2024-12-04	SPRYARS Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−45K sh	—	—	149,640
2024-12-03	SPRYARS Pharmaceuticals, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+3,260 sh	$0.84	+$2,738.4	139,640
2024-12-03	SPRYARS Pharmaceuticals, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+41.7K sh	$0.84	+$35.1K	181,380
2024-12-03	SPRYARS Pharmaceuticals, Inc.S Sale	Chief Business Officer	SSale	−45K sh	$13.19	−$593K	136,380
2024-12-03	SPRYARS Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−3,260 sh	—	—	0
2024-12-03	SPRYARS Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−41.7K sh	—	—	194,640
2024-12-02	SPRYARS Pharmaceuticals, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+45K sh	$0.84	+$37.8K	181,380
2024-12-02	SPRYARS Pharmaceuticals, Inc.S Sale	Chief Business Officer	SSale	−45K sh	$13.67	−$615K	136,380
2024-12-02	SPRYARS Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−45K sh	—	—	3,260
2024-11-27	SPRYARS Pharmaceuticals, Inc.S Sale	Chief Business Officer	SSale	−25K sh	$14.39	−$360K	136,380
2024-11-26	SPRYARS Pharmaceuticals, Inc.S Sale	Chief Business Officer	SSale	−42.2K sh	$14.05	−$593K	161,380
2024-11-25	SPRYARS Pharmaceuticals, Inc.S Sale	Chief Business Officer	SSale	−32.8K sh	$14.00	−$459K	203,566
2024-01-02	SPRYARS Pharmaceuticals, Inc. · Stock option (right to buy)A Award	Chief Business Officer	AAward	+350K sh	—	—	350,000
2023-01-03	SPRYARS Pharmaceuticals, Inc. · Stock option (right to buy)A Award	Chief Business Officer	AAward	+165K sh	—	—	165,000
2022-11-08	SPRYARS Pharmaceuticals, Inc.A Award	Chief Business Officer	AAward	+236K sh	—	—	236,380
2022-11-08	SPRYARS Pharmaceuticals, Inc. · Stock option (right to buy)A Award	Chief Business Officer	AAward	+236K sh	—	—	236,380
2022-11-08	SPRYARS Pharmaceuticals, Inc. · Stock option (right to buy)A Award	Chief Business Officer	AAward	+236K sh	—	—	236,380
2022-11-08	SPRYARS Pharmaceuticals, Inc. · Stock option (right to buy)A Award	Chief Business Officer	AAward	+48.3K sh	—	—	48,260
2022-11-08	SPRYARS Pharmaceuticals, Inc. · Stock option (right to buy)A Award	Chief Business Officer	AAward	+82.7K sh	—	—	82,733

Recent filings

Accepted (ET)
Jan 54
Chakma Justin0001951238-26-000003
SEC(opens sec.gov)
Nov 144
Chakma Justin0001951238-25-000005
SEC(opens sec.gov)
Jan 34
Chakma Justin0001415889-25-000461
SEC(opens sec.gov)
Dec 134
Chakma Justin0001415889-24-029377
SEC(opens sec.gov)
Dec 124
Chakma Justin0001415889-24-029162
SEC(opens sec.gov)
Dec 64
Chakma Justin0001415889-24-028567
SEC(opens sec.gov)

Companies

ARS Pharmaceuticals, Inc.Chief Business OfficerSPRY

Address

C/O ARS PHARMACEUTICALS, INC. 11682 EL CAMINO REAL, SUITE 300

SAN DIEGO, CA, 92130